DXCM
DexCom, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-12
Figures on this page computed 2026-11-08 12:48 UTC
Last close
88.48USD
Market data, 2026-11-04
Except where said otherwise: 10-K for 2025, filed 2026-02-12
37.1xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-02-12
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-10-29
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-10-29
17.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
23.1%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
- 10-K for 2025, filed 2026-02-12
- 10-K for 2025, filed 2026-02-12
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
- 10-K for 2025, filed 2026-02-12
- 10-Q for 2025, filed 2026-10-29
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.16 against 0.37 on the market's range.
- Growth19.3%65 of 100, above its sector
- Returns on capital30.5%93 of 100, above its sector
- Margins60.1%83 of 100, above its sector
- Price37.1x16 of 100, below its sector
- Safety1.8876 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 4- Profit on each unit of sales17.9%14.4%Ahead
Higher is better here.
- Return on the capital it usesn/a9.0%n/a
Higher is better here.
- Sales growth over five years19.3%15.2%Ahead
Higher is better here.
- Debt against equityn/a0.50n/a
Lower is better here.
- Gross margin60.1%69.0%Behind
Higher is better here.
- Price against earnings37.1x21.8xBehind
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Boston Scientific Corporation, DXCM is behind on 2 of 4 measures.
Against Boston Scientific Corporation, DXCM is behind on 2 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-02-12
Profit on each unit of sales17.9%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
Sales growth over five years19.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
Debt against equityn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
Gross margin60.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD
Price against earnings37.1x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001093557-26-000027
- Reported in
- USD